Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	colorectal cancer
ICD-0-3	C19.9
Methods	qPCR, Western blot, in vitro knockdown
Sample	human colon normal epithelial cell line (NCM460) and CRC cell lines (HCT-116, LoVo, SW480, SW620, and HT-29), CRC tissues and adjacent normal mucosal tissues
Expression Pattern	up-regulated
Function Description	we report the identification of a novel lncRNA, named long non-coding RNA regulating IL-6 transcription (LNRRIL6), which is upregulated in CRC tissues and cell lines. Increased LNRRIL6 expression is associated with aggressive clinicopathological characteristics and poor prognosis of CRC patients. Functional experiments showed that enhanced expression of LNRRIL6 promotes CRC cell proliferation and survival in vitro and CRC tumor growth in vivo. Conversely, depletion of LNRRIL6 inhibits CRC cell proliferation and survival in vitro and CRC tumor growth in vivo. Mechanistically, we revealed that LNRRIL6 physically binds to the IL-6 promoter, thereby increasing IL-6 transcription, inducing IL-6 autocrine signaling, and activating the IL-6/STAT3 pathway. The expression of IL-6 is positively associated with that of LNRRIL6 in CRC tissues. Blocking the IL-6/STAT3 pathway using the FDA-approved IL-6-receptor antagonist antibody, tocilizumab, abolished the oncogenic role of LNRRIL6 in CRC.
Pubmed ID	31246342
Year	2019
Title	LNRRIL6, a novel long non-coding RNA, protects colorectal cancer cells by activating the IL-6-STAT3 pathway

External Links